Literature DB >> 10765421

Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics.

H J Clewell1, J M Gearhart, P R Gentry, T R Covington, C B VanLandingham, K S Crump, A M Shipp.   

Abstract

An analysis of the uncertainty in guidelines for the ingestion of methylmercury (MeHg) due to human pharmacokinetic variability was conducted using a physiologically based pharmacokinetic (PBPK) model that describes MeHg kinetics in the pregnant human and fetus. Two alternative derivations of an ingestion guideline for MeHg were considered: the U.S. Environmental Protection Agency reference dose (RfD) of 0.1 microgram/kg/day derived from studies of an Iraqi grain poisoning episode, and the Agency for Toxic Substances and Disease Registry chronic oral minimal risk level (MRL) of 0.5 microgram/kg/day based on studies of a fish-eating population in the Seychelles Islands. Calculation of an ingestion guideline for MeHg from either of these epidemiological studies requires calculation of a dose conversion factor (DCF) relating a hair mercury concentration to a chronic MeHg ingestion rate. To evaluate the uncertainty in this DCF across the population of U.S. women of child-bearing age, Monte Carlo analyses were performed in which distributions for each of the parameters in the PBPK model were randomly sampled 1000 times. The 1st and 5th percentiles of the resulting distribution of DCFs were a factor of 1.8 and 1.5 below the median, respectively. This estimate of variability is consistent with, but somewhat less than, previous analyses performed with empirical, one-compartment pharmacokinetic models. The use of a consistent factor in both guidelines of 1.5 for pharmacokinetic variability in the DCF, and keeping all other aspects of the derivations unchanged, would result in an RfD of 0.2 microgram/kg/day and an MRL of 0.3 microgram/kg/day.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10765421     DOI: 10.1023/a:1007017116171

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  24 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

Authors:  Lu Gaohua; Khaled Abduljalil; Masoud Jamei; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Cardiac Output and Its Distribution to Different Organs during Development.

Authors:  Khaled Abduljalil; Xian Pan; Ruth Clayton; Trevor N Johnson; Masoud Jamei
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

Review 4.  Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.

Authors:  Sílvia M Illamola; Christina Bucci-Rechtweg; Maged M Costantine; Ekaterini Tsilou; Catherine M Sherwin; Anne Zajicek
Journal:  Br J Clin Pharmacol       Date:  2017-10-22       Impact factor: 4.335

5.  Estimating Methylmercury Intake for the General Population of South Korea Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Seungho Lee; Yu-Mei Tan; Martin B Phillips; Jon R Sobus; Sungkyoon Kim
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

6.  Impacts of farmed fish consumption and food trade on methylmercury exposure in China.

Authors:  Maodian Liu; Long Chen; Yipeng He; Zofia Baumann; Robert P Mason; Huizhong Shen; Chenghao Yu; Wei Zhang; Qianggong Zhang; Xuejun Wang
Journal:  Environ Int       Date:  2018-08-13       Impact factor: 9.621

7.  A generalized physiologically-based toxicokinetic modeling system for chemical mixtures containing metals.

Authors:  Alan F Sasso; Sastry S Isukapalli; Panos G Georgopoulos
Journal:  Theor Biol Med Model       Date:  2010-06-02       Impact factor: 2.432

8.  Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages.

Authors:  Anne E Loccisano; Matthew P Longnecker; Jerry L Campbell; Melvin E Andersen; Harvey J Clewell
Journal:  J Toxicol Environ Health A       Date:  2013

9.  Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine.

Authors:  Sungkyoon Kim; David Kim; Gary M Pollack; Leonard B Collins; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2009-05-03       Impact factor: 4.219

10.  Variability and epistemic uncertainty in water ingestion rates and pharmacokinetic parameters, and impact on the association between perfluorooctanoate and preeclampsia in the C8 Health Project population.

Authors:  Raghavendhran Avanasi; Hyeong-Moo Shin; Veronica M Vieira; Scott M Bartell
Journal:  Environ Res       Date:  2016-01-19       Impact factor: 6.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.